Health & Fitness
Tue, January 22, 2013Mon, January 21, 2013Fri, January 18, 2013Thu, January 17, 2013Wed, January 16, 2013Tue, January 15, 2013Mon, January 14, 2013Fri, January 11, 2013Thu, January 10, 2013Wed, January 9, 2013Tue, January 8, 2013Mon, January 7, 2013Sun, January 6, 2013Fri, January 4, 2013Thu, January 3, 2013Wed, January 2, 2013Mon, December 31, 2012Fri, December 28, 2012Thu, December 27, 2012Wed, December 26, 2012Mon, December 24, 2012Fri, December 21, 2012Thu, December 20, 2012Wed, December 19, 2012Tue, December 18, 2012The Medicines Company Completes Acquisition of Incline Therapeutics, Inc.
//health-fitness.news-articles.net/content/2013/ .. tes-acquisition-of-incline-therapeutics-inc.html
Published in Health and Fitness on Monday, January 7th 2013 at 6:15 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
January 07, 2013 09:00 ET
The Medicines Company Completes Acquisition of Incline Therapeutics, Inc.
PARSIPPANY, NJ and REDWOOD CITY, CA--(Marketwire - Jan 7, 2013) - The Medicines Company (
Glenn Sblendorio, President and Chief Financial Officer said, "This is another step to establish The Medicines Company as a leader in acute and intensive care medicine globally. We have been very impressed with the work that the Incline team has done with IONSYS and look forward to collaborating with our team in Redwood City to continue preparing the product for near-term resubmission for marketing approval in the US and Europe."
About The Medicines Company
The Medicines Company (
Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions, including the Company's preliminary revenue results, are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include the extent of the commercial success of Angiomax, the Company's ability to develop its global operations and penetrate foreign markets, whether the Company's products will advance in the clinical trials process on a timely basis or at all, whether the Company will make regulatory submissions for product candidates on a timely basis, whether its regulatory submissions will receive approvals from regulatory agencies on a timely basis or at all, whether physicians, patients and other key decision makers will accept clinical trial results, risks associated with the establishment of international operations; the ability of the Company to retain certain key employees of Incline; decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of IONSYS for its current or potential new indications; the ability of the Company to obtain marketing approvals and launch IONSYS when planned; the extent of commercial success of IONSYS; the ability of the Company to successfully integrate Incline's business with the Company's other businesses and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed on November 9, 2012, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.